AJU C714
Alternative Names: AJU-C714Latest Information Update: 04 Jul 2025
At a glance
- Originator AJU Pharm
- Class Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Dyslipidaemias
Most Recent Events
- 24 May 2025 Phase-I clinical trials in Dyslipidaemias in South Korea (unspecified route) (In volunteers) (NCT06933459)